LMAT:NASDAQLeMaitre Vascular, Inc. Analysis

LeMaitre Vascular (LMAT) is trading at $91.38, well above its DCF fair value of $56.62 and its 20‑day SMA of $95.97, indicating a significant premium. The stock’s forward P/E of 28.1 also exceeds the industry average of 24.9, reinforcing an overvalued valuation. Technical indicators show a neutral trend with the price hovering just above the identified support of $90.28, while the 14‑day RSI at 34.5 suggests the stock is approaching oversold conditions. A bullish MACD histogram (+0.18) and a MACD line crossing above its signal line add a modest upside bias, though volatility remains high at 35.5% over the past 30 days and beta is modest at 0.64. Recent news of management presenting at two investor conferences in June could provide short‑term visibility and potentially tighten the price range around the support level.
Fundamentally, LMAT posted 11.2% revenue growth, strong gross (71%) and operating margins (27%), and generated $87.3 M of operating cash flow, supporting a sustainable dividend yield of 1.08% with a low 31% payout ratio. The balance sheet is solid with $368 M in cash against $190 M of debt, yielding a debt‑to‑equity of 46.7%. While the stock appears overvalued in the near term, its cash generation, dividend sustainability, and global market exposure suggest a more favorable outlook over medium to long horizons.